Patients suffering from dry eye disease symptoms now have another treatment option. The Food and Drug Administration has announced its approval of Tryptyr as a new dry eye disease therapy.
Tryptyr works differently from other dry eye disease options by stimulating corneal sensory nerves to stimulate natural tear production. Tryptyr eye drops will be available in single-dose vials with the recommended dosage of one drop in each eye twice daily.
Clinical study results showed that Tryptyr greatly enhanced natural tear production even on the first day of use. Minimal adverse reactions were reported with the most common one being pain at the site of drop instillation.
Tryptyr is manufactured by Alcon and the company expects the ophthalmic drops to be made available in the United States by the third quarter of 2025.
